LDS/Medical Tests/Polycystic Kidney Disease, Autosomal Recessive (PKHD1), Gene Analysis

Polycystic Kidney Disease, Autosomal Recessive (PKHD1), Gene Analysis

Classic Autosomal Recessive Polycystic Kidney Disease (ARPKD) is characterized by oligohydramnios and pulmonary hypoplasia in utero, and congenital hepatic fibrosis (Caroli's disease). ARPKD is characterized by enlarged echogenic kidneys, congenital hepatic fibrosis, and pulmonary hypoplasia (secondary to oligohydramnios). Most individuals with ARPKD present with symptoms during the neonatal period and, of those, nearly one-third die of respiratory insufficiency. Early diagnosis is necessary for disease management such as dialysis and when possible renal transplant as well as respiratory support, which often increases survival rate significantly. Presenting symptoms include bilateral palpable flank masses in infants and subsequent observation of typical findings on renal ultrasound, often within the clinical context of hypertension and prenatal oligohydramnios. Its prevalence is approximately 1:20,000 live births. As the name indicates this is an autosomal recessive disorder and it demonstrates 100% penetrance.

ARPKD is most commonly caused by mutations in the polycystic kidney and hepatic disease 1 (PKHD1) gene. p12.2. The PKHD1 is a large gene located at chromosome 6p12 and contains 67 exons. The gene encodes a protein called fibrocystin, which is localized to the primary cilia and basal body of renal tubular and biliary epithelial cells. Sine ARPKD is an autosomal recessive disease, affected individuals carry two or more mutations in the PKHD1 gene. The severity of disease depends on the mutation type and location. Although the initial diagnosis of disease is made by imaging, mutation detection by sequencing is usually performed to confirm the diagnosis and determine the specific mutation(s) involved. Due to its large size, PKHD1 mutation detection is typically based on sequencing of the entire gene.

  • As an aid in diagnosis of Autosomal Recessive Polycystic Kidney Disease
  • Carrier testing of individuals with a family history of ARPKD and prenatal care
Homozygous mutation or compound heterozygous mutations confirms diagnosis. Pathogen variants are reported based on American College of Medical Genetics recommendations. Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

Negative for mutation analysis (No pathogenic mutations detected)

Targeted or whole gene sequencing by Next Generation Sequencing (NGS), Target sequencing by conventional sequencing, other molecular methods.

Whole blood in a lavender top (EDTA) tube. Buccal swabs with appropriate transport media.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
Mutations in PKD1 and PKD2 genes to rule out Autosomal Dominant Polycystic Kidney Disease (ADPKD), ADPKD III (ADPKD3) mutations can be considered.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login